# Sunstone Health

AI-powered precision health platform for kids with genetic diseases. 

- Canonical URL: https://wefunder.com/sunstone.health
- Entity ID: wefunder:company:180147
- Last updated: 2026-06-04T21:34:50Z
- Generated at: 2026-06-05T02:45:57Z

## Quick facts
- Reduces 7-year diagnostic odyssey into a 12-week precision care solution
- Proven with >400 families, 90% opt-in, active with major US health plans
- AI powered pattern recognition finds kids with genetic diseases in claims data
- First-to-market, trade-secret and method-patented model built for scale
- Partnered with NVIDIA Inception Program, Creative Destruction Lab Computational Health Cohort 2024
- Backed by team of Advisors and Investors with Billions in successful exits

## Active fundraises
- wefunder:fundraise:140199: 4(a)(6) successful (USD)
- wefunder:fundraise:140198: 4(a)(6) successful (USD)

## Story
AI to Power the Healthcare Revolution1 in 31 kids has autism. In today's system, the path to a genetic answer takes years. With Sunstone's AI, it's 12 weeks.$1M left to close our Series A. $8.5M valuation set by Saturn Partners. 6.5M+ lives in our pipeline. Pilots live now.What we do.We end the diagnostic odyssey — years of wrong specialists, wrong tests, and wrong treatment. It's the single biggest cost sink in genetic disease.How we do it.We sell self-insured employers a benefit for their employees' families.Our AI finds the kids in the claims data. Broad Clinical Labs sequences their genome. Our doctors deliver a plan to their doctor.12 weeks, end to end. Not 7 years.Why autism is broken.1 in 31 kids. ABA therapy costs employers $40K–$60K per child per year.Autism is deeply genetic. About 30% of cases have an identifiable genetic cause today, and that number grows every year as the science improves. But fewer than 20% of kids with autism ever get a genetic test — even though every major pediatric board recommends it.So therapy gets built on guesswork. A child gets the wrong care for years. One undiagnosed case can cost $3.1M over a lifetime.The kids are in the data. Nobody is looking.Christopher. Age 7.Before Sunstone: 40 hours of therapy a week. No plan. No genetic test. $58,400/year.After Sunstone: Fragile X found. Therapy rebuilt around it. Real progress in 6 months. $21,200/year.64% less money. A child with a plan. A family with answers.How we make money.$10,000 per case we solve. Flat fee. Paid only after we deliver the doctor-to-doctor care plan.One case that breaches a $250K stop-loss = 25× ROI. And the employee gets something priceless: real answers for their kid.60%+ gross margin at scale.Autism today. Every genetic disease tomorrow.We start with autism — the pain is real, the market is big, the genetics are clear.Then: pediatric epilepsy. Rare disease. Adult genetic conditions. The identification layer we build for autism becomes the layer for every genetic disease in employer health plans.Where we are.6.5M+ lives in active pipelineFortune 50 telecom — NDA signed, principal benefits buyerNational grocery chain — pilot explorationCare management platform — 200K lives, contract finalizationBroad Clinical Labs — signed lab deal with the institution behind the Human Genome ProjectAdvisors from Mass General Brigham, Medco, Illumina, Proteus, Alva10We have contracts on the table.Why I built this.I'm Joshua. Biomedical engineer, Harvard-trained. My son has PFAPA — a rare autoimmune condition with no treatment.I know what the system does to families who don't fit its script. I lived it.So I built what we all needed.The round. Raising$1M to closePre-money$8.5M — Saturn Partners, 1× prefRevenuePay-for-results — only on deliveryUse of fundsClose pilots, scale ops, launch 1/1/27Why community.We could have closed this with institutions. We chose you.Because the people who understand why Sunstone matters are the ones who've lived it. Parents. Clinicians. Benefits pros. Anyone who's watched the system fail a kid.We want you in. Not for the check. For the army.Startup investing is risky. You may lose your entire investment. See Form C on Wefunder for full terms.

## FAQ
1. **Your program sounds impressive and seems like a win-win-win for all involved. I have a few clarifying questions: The overview mentions a raise of $5M, but the top section lists a goal of $3.59M. Is there a discrepancy, or am I misinterpreting something? What is the exit strate...**
   - Hi Alan and Leah - Thank you for your interest! We have worked extremely hard to make sure all parties win to drive adoption and scale. I have added additional clarifying information to the documentation and had Wefunder correct the displayed goal, apologies for the confusion. The full Series A round is for $5M. We have set aside $400,000 for our community to engage through Wefunder (with the remainder in discussion with other strategic and/or institutional investors). Our lead investor Satur...
2. **hOW MUCH IS A SHARE WORTH NOW, TODAY?**
   - $0.9034
3. **I came across your Crowdfunding campaign on Wefunder and wanted to reach out. The Backer Hive is an invite-only club for serious backers interested in crowdfunding campaigns. With over 300k subscribers to our newsletter, we offer excellent rates to help promote your project th...**
   - Thanks Saheed
4. **I came across your Crowdfunding campaign on Wefunder and wanted to reach out. The Backer Hive is an invite-only club for serious backers interested in crowdfunding campaigns. With over 300k subscribers to our newsletter, we offer excellent rates to help promote your project th...**
   - Thanks Saheed
5. **I and interested, but have 2 quick questions. 1. Are we buying shares in this round, or it's simply pre-money SAFE which leads to per % of ownerships? 2. When was the company founded, and how much revenue so far?**
   - Thanks for your interest Yubing! The company was founded at the end of 2019 and we spent a few years doing research and running a pilot out of Medellin Colombia. In 2023 we took the lessons and data we developed to reorganize as a scalable, software first platform, and starting actively selling to self-funded health plans in Q4 2024. We are currently pre-revenue, but have contracts that represent ~250,000 lives, and have a $2.3M revenue horizon for 2025. You are buying Series A preferred shar...

## Team
- Joshua Resnikoff (CEO + Cofounder)
- Calum MacRae (Head of Innovation)
- Sofia Giraldo (Director of Operations)
- Paterson Anaccius (Lead Full Stack Developer)
- Jonathan Calixte (Full Stack Developer)
- Cameron Pearson (Automation Architect)
- Martin Grasso (CCO + Cofounder)
- Dr. Javier Romero (Lead Medical Advisor)

## Recent posts
- Heads Down, Moving Forward. (2026-04-15T17:14:51Z)
- Sunstone in Reuters! (2026-02-20T16:24:48Z)
- March 4 - Community Update (2026-02-19T22:24:25Z)

## Q&A
- Q: Will this investment qualify for QSBS status allowing investors to avoid cap gains on up to $15M of sale proceeds? Thx.
  - A: Hi Mike, Thanks for your question. Disclaimer: WE CANNOT PROVIDE YOU WITH TAX ADVICE AND HAVE NOT CONSULTED WITH A TAX PROFESSIONAL ON YOUR SPECIFIC QUESTION. However, given the fact that a professional lead investor has set the price of these shares at a level that exceeds the de minimis threshold standard for qualifying for QSBS or Rule 83-b treatment, and other professional investors have purchased our preferred shares at this level, it seems unlikely that these shares will qualify for QSBS treatment. Thanks for your interest in TMA!
- Q: Joshua, A brilliant video briefly telling your personal story that demonstrates you and your teams specific abilities to deliver. I am a huge believer in, and personally benefited from precision medicine to drastically reduce diagnosis from years to weeks. From your presentation,"We’re Focused on Serving Self-Funded Employers Covering healthcare costs directly for 65% of the insured U.S. population, employers that offer self-funded insurance plans have a dedicated interest in their members’ health and satisfaction, and a financial responsibility to contain costs — and they can move fast when a solution works. With 90% patient opt-in and a pay-for-results model, TMA offers them a no-risk turnkey solution to improve care and decrease spend while improving member outcomes." The 23andMe DNA patient database was a risk of being sold to the highest bidder when in bankruptcy court. However, I believe you have an exceptional plan for success. The 90% patient opt-in rate might drop if there is fear of being DNA identified as a costly risk. How do you encourage a, "With 90% patient opt-in and a pay-for-results model" to prevent insurance companies from refusing to renew patient insurance policies? Regards, Allen
  - A: Great question Allen, and thanks so much for your interest! Your question strikes right to the core of GINA, which is federal law that prohibits discrimination based on genetic information in health coverage and employment. Because we take patient data security very seriously, we go a step further by engaging directly with the patient for consent, and never sharing their information back with the insurer. The net is that the patients own their personal data and we provide them the "right to be forgotten"; they have full control over permissions to who can - and can not - access their data. As parents and patients ourselves, its an area we are extremely keen about protecting patient privacy on. Happy to go deeper anytime, and thanks for your support! Josh
- Q: Very interesting concept. I would like to invest 10k. Can you confirm the price per share and the evaluation that I would be investing at. Are these preferred shares. Will I be receiving the 8% dividend. Thanks
  - A: Hello Yaakov, Thanks for your interest in TMA! The share price set by the lead investor is $.90342. These are for 1x preferred shares that accrue an 8% dividend that will be paid at the discretion of the board. We would love to have you on board before the round closes! Kind regards, Marty Grasso
- Q: The link I was looking for is to the webinar from Wednesday, August 6th at 1pm PST with Joshua Resnikoff and Travis Lacey, the CEO of Simplify Genomics
  - A: No worries Mark, thanks for asking! I will be sending out an update as well, but here is the link and the passcode: https://us06web.zoom.us/rec/share/bk2VF_vNAtNle5LTQMIWxnL6ZEnYk-4yes7gJ9IzbHv8FRvTOl3F-fc9jYDV9Hp6.2sEAttnz_ZR0b5jm Passcode: V%2Pz2FM
- Q: Can you please provide a link to the investor and commercial update presentation? I just saw this today.
  - A: Hi Mark, Many thanks for your interest! If you scroll down on our offering page (https://wefunder.com/tmaprecisionhealth/), you will find all of the sections that you are looking for (Overview, Details, Updates, What People Say and Ask a Question) as live links to each of those categories. Please let me know if we can answer any additional questions that you may have as they arise. Kind regards, Marty Grasso
- Q: I asked questions back in June. Now 2 months passed. How does the numbers you mentioned below back in June look like now? "We are currently pre-revenue, but have contracts that represent ~250,000 lives, and have a $2.3M revenue horizon for 2025." Also, if I invest today, when will this funding cycle approximately close? In other words, how soon will the shares in this round be allocated to investors?
  - A: Hello Yubing. Thank you for the outreach. We are still on track for the contractual revenue projected, and our pipeline grows larger every week. We expect to reach our fundraising threshold for a first closing ($3million) by the end of the month of August, given that we are only ~$55K short of that and raising new capital at a good clip every day. We will then have the first closing and allocate investor shares concurrently. I hope this answers your questions. Thank for your interest in TMA Precision Health!
- Q: What is the current price per share
  - A: $0.9034
  - A: Hi John, Thanks for your interest in TMA Precision Health. The current price of the Preferred Shares for our offering is $0.90342/share. The shares come with a 1x preference and an 8% accrued dividend. Please let us know if you have any further questions.
- Q: Questions will this be available for all level of health plans. If this is to scale into a "go to help" then it should be accessible to all levels of health plans in all insurance companies.
  - A: Hi Edmond, thanks for the great question - 100% it works with, and will be available to, all levels of plans across all insurance companies. We're in conversation with the big guys (Blues etc) and already working with self-funded employer plans. Let me know if I can answer anything else? Thanks! Josh
- Q: Is my initial investment still included?
  - A: Yes, all investments that have been committed are included, thank you for your support!
- Q: Hi Joshua, I'm invested in SEVERAL pre-IPO's!! So I'm going to be frank here!! My any only interest is any idea when you'll be going public so I can hopefully see some return on my investment....
  - A: Hi Vicky, great question! Our more likely path is to exit via M&A in the next few years, based on similar companies in our space (and you should see the comps!). We work hard not to be just excellent stewards of capital, but aim to provide a great return - call it our professional experience in the space. I hope you will join us!!
- Q: How much revenue will be booked at the end of 2025? And how many patients are signed up currently? And what’ll do you have a guaranteed revenue number for q1 of 2026 based off signed contracts?
  - A: Hi Eliezer, thanks for your question. We're currently working with 10 patients and are in conversation with US employers in the 5,000+ member range, TPA's in the 100,000+ member range, and stop-loss insurance in the 1,000,000+ member range, aiming to get into the 1/1 start cycle. I would not put a "guaranteed revenue" number on the table for Q1 2026, but based on the above conversations I am extremely bullish about our prospects. Please let me know if I can answer anything else? Thanks! Josh
- Q: Will you be extending this round?
  - A: 100% - should reopen at the end of the month! But you can commit today in advance. Thanks for your support!
- Q: I WANT TO ADD $1000 TO MY EXISTING INVESMENT IN TMA Precision Health AND CAN'T FIND A WAY TO DO THAT.
  - A: Thanks for your intent to invest more, Harold. We really appreciate your confidence! Just go to the TMA Campaign page and select the "Learn" menu in the upper right. From the drop down menu select "Investor FAQ". You will see a menu of choices on the left side from which you should choose "Refunds and Reinvesting". You should then see a list of "How to" instructions which include explicit instructions about how you can increase your investment, complete with examples. Please let me know if I can assist with anything else and thanks again for your commitment to our mission at TMA!
- Q: Can you explain what you guys do and the steps you go through after you identify a patient and sequence their genome up until you get paid for completing the case? Thanks
  - A: We will coordinate all of the diagnostics, genetic counseling, and medical review required to provide clinically specific doctor-to-doctor guidance that gets delivered back to the patient and their local care team for diagnosis and treatment implementation. We only charge employers when we deliver that package of information - so employers know that they are paying for a service that is being used by their members, not just a balloon subscription PEPM that has low utilization rates.
- Q: Having invested in several pre-Ipos, I have experienced mostly the downside of the timeframes most ventures place on thier visions. One such example occurred on the Wefunder platform to build value by attracking donors. My surprise was when I spoke directly with the President of the venture. Their time frame was 7 years out! Despite having a viable product, making the Guiness Book of World Records for an autonomous dead weight lift by their design methodology, as wll as awarded a $48+M Federal DOD contract to use their product, they were determined to seek and vett all suitors. In the meantime, my investment is stagnant; 2) the sale is not guaranteed to come to fruition in seven years; 3) my control is limited at best, and 4) There is no qurantee they could go public, thus depriving me of potential lucrative gains in an IPO. Essentially, buyer beware.